вторник, 17 января 2017 г.

Biogen in $1.25 billion deal with Forward Pharma to protect MS drug

Biogen in $1.25 billion deal with Forward Pharma to protect MS drug


Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to gain access to the Danish company's intellectual property as it seeks to protect the patent life of its flagship multiple sclerosis drug, Tecfidera. LONDON Carlyle Group has agreed to become the largest shareholder in Johannesburg-based Global Credit Ratings , the U.S. buyout fund said on Tuesday, looking to broaden the pan-African ratings agency's services.



from Biotech News